Indian stocks: Visit www.stage2stocks.com →

Filana Therapeutics, Inc.

Stage 4 · Declining · week 36

As of Oct 22, 2026, Filana Therapeutics is in Stage 4, the downtrend phase, now in week 36 (since Feb 5, 2026). It closed at $0.65, 83.4% below its 52-week high and below its 200-day average, which is falling.

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. More about the company

$0.65
-3.40% today
$31.6M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is FLNA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 15w
S2 13w
S4 37w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 13w → S1 6w → S2 9w → S3 10w → S4 1w → S3 1w → S2 2w → S1 1w → S4 8w → S1 4w → S2 8w → S3 5w → S4 15w → S1 1w → S4 12w → S1 13w → S2 13w → S3 6w → S4 37w current
Total tracked: 165 weeks across 19 stage runs.

FLNA among Biotechnology477th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…477FLNAStage 4 · wk 3610−25.3%
vs 52W High
-83.4%
$0.65 lo$3.91 hi
83.4% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 36
1w13w26w
Week 36, extended decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-53.6%
200 DMA: $1.40 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.10x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-25.3%
3M
-27.0%
6M
-60.8%
YTD
-68.9%
1Y
-83.7%
Scan Membership
Breakout Watch
Latest: 2024-09-13
10 appearances in last 60 days. First seen: 2019-07-08.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 36 · Vol 0.10x
2026-10-21S4
Wk 36 · Vol 0.12x
2026-10-20S4
Wk 36 · Vol 0.08x
2026-10-19S4
Wk 36 · Vol 0.10x
2026-10-16S4
Wk 36 · Vol 0.13x
2026-10-15S4
Wk 35 · Vol 0.10x
2026-10-14S4
Wk 35 · Vol 0.10x
2026-10-13S4
Wk 35 · Vol 0.13x
2026-10-12S4
Wk 35 · Vol 0.14x
2026-10-09S4
Wk 35 · Vol 0.16x
2026-10-08S4
Wk 34 · Vol 0.24x
2026-10-07S4
Wk 34 · Vol 0.31x
Moving averages & range
50 DMA
$0.83
200 DMA
$1.40
52W High
$3.91
52W Low
$0.65
5D Low
$0.65
Resistance levels (recent highs)
20d High
$0.97
60d High
$1.03
120d High
$1.55
250d High
$3.80
Next resistance
+49.2%
to 20d High
ROE
-55.8%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 0.5

Filana Therapeutics: quick answers

What stage is Filana Therapeutics in?

As of Oct 22, 2026, Filana Therapeutics (FLNA) is in Stage 4, the downtrend phase. It entered Stage 4 on Feb 5, 2026 and is in week 36. What the four stages mean

Is Filana Therapeutics in an uptrend?

No. Filana Therapeutics is in a Stage 4 downtrend. It trades 53.6% below its 200-day average, which is falling.

How far is Filana Therapeutics from its 52-week high?

Filana Therapeutics closed at $0.65 on Oct 22, 2026, 83.4% below its 52-week high of $3.91. Its 52-week low is $0.65.

How has Filana Therapeutics performed over the past year?

As of Oct 22, 2026, Filana Therapeutics is down 83.7% over the past year and down 68.9% so far in 2026.

Which sector and industry is Filana Therapeutics in?

Filana Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.